What second-line chemotherapy regimens are recommended for a patient with recurrent ovarian cancer who has progressed after first-line platinum‑taxane therapy, based on platinum-sensitive versus platinum-resistant disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Second-Line Chemotherapy for Recurrent Ovarian Cancer

For platinum-sensitive recurrent ovarian cancer (relapse >6 months after last platinum), use a platinum-based doublet—specifically carboplatin plus paclitaxel, carboplatin plus pegylated liposomal doxorubicin (PLD), or carboplatin plus gemcitabine—with bevacizumab added for patients requiring rapid response, followed by PARP inhibitor maintenance only in BRCA1/2-mutated patients who are PARP inhibitor-naïve 1, 2, 3.

Platinum-Sensitive Disease (Relapse >6 months)

Primary Treatment Approach

The cornerstone of second-line therapy remains platinum-based combination chemotherapy. Three doublet regimens have equivalent efficacy 1, 3:

  • Carboplatin + paclitaxel
  • Carboplatin + PLD
  • Carboplatin + gemcitabine

Recent retrospective data suggests carboplatin + PLD may have shorter progression-free survival compared to taxane-platinum regimens in platinum-sensitive patients (HR 1.67, p=0.016), making carboplatin + paclitaxel or carboplatin + gemcitabine preferable first choices 4.

Bevacizumab Integration

Add bevacizumab to the platinum doublet followed by bevacizumab maintenance for patients requiring rapid response 1, 3. The AURELIA trial demonstrated improved PFS, response rates, and quality of life with bevacizumab addition. Continue bevacizumab until symptomatic progression or next treatment line—continuation beyond progression lacks evidence 1.

Critical caveat: Bevacizumab should be avoided in patients with bowel obstruction history, serosal invasion, or progression during first-line platinum due to intestinal fistula risk 1.

Maintenance Therapy: PARP Inhibitors

PARP inhibitor maintenance is now restricted to BRCA1/2-mutated patients only following FDA regulatory changes in 2022-2024 2. This restriction arose from retrospective analyses showing no OS benefit and potential harm in BRCA wild-type patients.

Specific indications 1, 2:

  • Olaparib: BRCA1/2-mutated (germline or somatic), PARP inhibitor-naïve
  • Niraparib: BRCA1/2-mutated (germline only), PARP inhibitor-naïve
  • Rucaparib: BRCA1/2-mutated (germline or somatic), PARP inhibitor-naïve

Continue PARP inhibitors until progression or next treatment line 1. The combination of bevacizumab plus PARP inhibitor is not recommended in recurrent disease 2.

Surgical Consideration

Evaluate all platinum-sensitive first relapses at a specialized gynecological oncology center for potential secondary cytoreductive surgery if complete gross resection appears achievable 1, 3.

Platinum-Resistant Disease (Relapse <6 months)

Definition Criteria

Platinum resistance includes 1:

  • Progression during platinum therapy (proven resistance)
  • Early symptomatic progression post-platinum (expected resistance)
  • Platinum intolerance
  • Patient choice/QoL considerations

First-Line Treatment: Mirvetuximab Soravtansine

For platinum-resistant high-grade disease with validated folate receptor alpha (FRα) expression, mirvetuximab soravtansine is the strongly recommended first choice 3. This antibody-drug conjugate represents the most significant advance in platinum-resistant disease.

Alternative Monotherapy Options

When mirvetuximab is not appropriate, recommended single-agent options include 1, 3:

  • Weekly paclitaxel (preferred over every-3-week dosing)
  • PLD monotherapy
  • Bevacizumab + chemotherapy (paclitaxel, PLD, or topotecan)
  • Relacorilant + nab-paclitaxel combination
  • Gemcitabine monotherapy (conditional alternative)

Bevacizumab addition to chemotherapy improves outcomes in platinum-resistant disease 1, 4. Omission of bevacizumab was associated with worse PFS (HR 2.01, p<0.001) in recent retrospective analysis 4.

Critical Management Points

  • Integrate palliative care early in platinum-resistant patients 1
  • Avoid combination non-platinum chemotherapy—no survival advantage over monotherapy 1
  • PARP inhibitors as monotherapy in platinum-resistant disease were withdrawn after ARIEL-4 showed worse OS, particularly in platinum-resistant subgroups 2

Key Decision Factors

Before selecting second-line therapy, assess 1:

  • Platinum-free interval (6-month cutoff for sensitivity; 12-month cutoff identifies better prognosis subgroup)
  • BRCA1/2 mutation status (determines PARP inhibitor eligibility)
  • Prior PARP inhibitor exposure (repeat use has limited data)
  • Prior bevacizumab exposure (AURELIA excluded previously exposed patients)
  • Histologic subtype (clear cell, carcinosarcoma, low-grade serous respond poorly to platinum)
  • Surgical resectability (for platinum-sensitive disease)
  • Performance status and residual toxicities

Special Histologic Subtypes

For low-grade serous carcinoma, consider MEK inhibitor trametinib over chemotherapy (improved PFS in phase III trial) or hormonal therapy (aromatase inhibitors, tamoxifen) for ER/PR-positive tumors 1.

Common Pitfalls

  • Using PARP inhibitors in BRCA wild-type patients (no longer indicated)
  • Combining bevacizumab + PARP inhibitor in recurrent setting (not recommended)
  • Continuing bevacizumab or PARP inhibitors beyond progression without evidence
  • Missing surgical cytoreduction opportunities in platinum-sensitive relapses
  • Using combination non-platinum chemotherapy in platinum-resistant disease

References

2
Guideline

nccn guidelines® insights: ovarian cancer/fallopian tube cancer/primary peritoneal cancer, version 3.2024.

Journal of the National Comprehensive Cancer Network : JNCCN, 2024

3
Research

Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026

Related Questions

What is the optimal chemotherapy regimen for a patient with relapsed, platinum‑refractory stage IV clear‑cell ovarian carcinoma?
What is the optimal chemotherapy regimen for a woman with stage IV clear‑cell ovarian carcinoma who has relapsed more than six months after her last platinum‑containing therapy (platinum‑sensitive disease)?
What are the recommended dosing regimens for bevacizumab, gemcitabine, and carboplatin in ovarian cancer treatment?
What is the evidence base for bevacizumab (Avastin) in epithelial ovarian, primary peritoneal, and fallopian‑tube cancer, including details of all clinical trials, their results, and subgroup analyses?
What is the recommended dosing and schedule of bevacizumab for newly diagnosed stage III–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer and for recurrent disease?
How should tirzepatide be initiated and titrated in an adult with type 2 diabetes inadequately controlled on metformin (or metformin + another oral agent) and a BMI ≥ 30 kg/m² (or ≥ 27 kg/m² with obesity‑related comorbidities), including dosing schedule, contraindications, monitoring, and management of adverse effects?
In a 20-year-old man with bacterial meningitis caused by Streptococcus pneumoniae (penicillin MIC 0.5 µg/mL intermediate, ceftriaxone MIC 0.1 µg/mL susceptible, vancomycin MIC 0.5 µg/mL susceptible) who is receiving ceftriaxone, vancomycin, and dexamethasone, what antibiotic regimen should be recommended?
What are the clinical implications and recommended management for a retroverted uterus?
What medication regimen is recommended for a patient with adjustment disorder presenting with anxiety and irritability?
What are the purpose of preoperative airway assessment, the conventional bedside airway assessment techniques, and the limitations of clinical airway assessment?
Is a hair tincture containing benzyl nicotinate, vitamin K, and salicylic acid safe and effective for promoting hair growth in an adult without allergies, open scalp wounds, or pregnancy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.